| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 89 | 4.9x | 17.6x | Top tier | |
Growth | 86 | 18.8% | 7.1% | Top tier | |
Quality | 76 | 7.5% | 4.5% | Top tier | |
Safety | 81 | — | 2.6x | Top tier | |
Capital Return | 81 | — | 2.15% | Top tier | |
Momentum | 52 | 1.3% | 2.3% | Around median | |
Sentiment | 64 | 3 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Innoviva, Inc. (listed on NASDAQ under the ticker INVA) is a company specializing in healthcare asset management and the development and commercialization of innovative medicines. The company generates its revenues primarily through royalties and intellectual property associated with respiratory products and other medications licensed to global pharmaceutical companies, alongside a growing portfolio of direct medicines and therapies that it owns or invests in to expand its footprint in the healthcare sector.
The financial results for the first quarter of 2026 demonstrated strong financial performance, with the company's total revenues reaching $98.0 million and generating a gross profit of $75.8 million. The company also recorded an exceptional net income of $186.6 million, which reflected positively on earnings per share (EPS), reaching $2.22 for this quarter, supported by the high margins that characterize its recurring revenue and licensing-based business model.
Looking at recent historical performance, in the fourth quarter and full fiscal year of 2025, the company achieved revenues of $411.3 million and net income of $271.2 million, with earnings per share of $3.3. These figures, along with the third quarter of 2025 revenues of $107.8 million, reflect the company's ongoing ability to generate strong and stable cash flows across multiple financial periods.
Automated analysis for informational purposes only — not investment advice.
Innoviva, Inc. stock is currently trading within a range clearly below the analysts' average price target of $40.00, with the stock's 52-week range spanning between $16.52 and $25.15. The current analyst consensus of 'Buy', with a high target of $46.00 and a low target of $32.00, indicates significant optimism regarding the stock's untapped intrinsic value and its future growth prospects.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
Innoviva, Inc. operates in healthcare asset management and drug development, focusing on generating financial returns through a portfolio of drug licenses and intellectual property rights, particularly in respiratory therapies. The company generates its profits primarily from royalty payments and intellectual property associated with these medications licensed to global companies, in addition to returns on its strategic investments in the healthcare and biopharmaceutical sectors.
The company recorded a strong financial performance in the first quarter of 2026, with total revenues reaching $98.0 million and achieving a gross profit of $75.8 million. Net income also jumped to reach $186.6 million, resulting in an excellent earnings per share of $2.22 during this single quarter. These figures reflect the company's continued financial strength and its high capability to convert revenues into net profits for shareholders.
INVA stock enjoys a consensus analyst recommendation of 'Buy', with an average price target set at $40.00. Analyst estimates range from a low target of $32.00 to an optimistic high target of $46.00. This consensus reflects market optimism regarding the company's financial future and its ability to deliver value to investors over the medium and long term.
Yes, on May 28, 2026, BTIG analysts issued positive ratings and assessments for Innoviva, Inc. (INVA) alongside other healthcare companies such as MDAI and NTHI. This positive rating strengthens the company's position in the market and indicates analyst confidence in the healthcare asset portfolio owned and managed by the company. This support from research firms serves as an important psychological and investment driver for the stock in the current period.
Although revenues for the first quarter of 2026 were $98.0 million, which is lower than the fourth quarter of 2025 revenues of $411.3 million, the first quarter net income of $186.6 million represents a strong continuation of the company's high profitability. Notably, total revenues for the full fiscal year 2025 were $411.3 million, and annual net income recorded $271.2 million with earnings per share of $3.3. This comparison demonstrates the company's financial resilience and its ability to achieve high net profits even during periods experiencing fluctuations in direct revenue volume.
